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INTRODUCTION RESULTS
CONCLUSIONS
Evaluation of Pharmacists’ Knowledge in Role of Naloxone Dispensing
 Rachel Perez MS4, Samantha Kennedy MS4, Rachel Haroz MD, Rachel Rafeq PharmD
Cooper University Hospital Department of Emergency Medicine 
METHODS
In response to the national opioid abuse and overdose crisis, New 
Jersey signed the Overdose Prevention Act (OPA) into law in May 
2013, allowing pharmacists in New Jersey to provide naloxone without 
a prescription through a standing order (1,2). Naloxone blocks the 
effects of opioids and can be used acutely to reverse an overdose, 
preventing respiratory failure and death. Despite the OPA, pharmacist 
education regarding naloxone and its distribution is lacking. A 
preliminary survey of pharmacists in Camden County, the county 
known to be the epicenter of opioid abuse in New Jersey, showed that 
many pharmacists are not fully aware of the implications and details 
regarding prescribing naloxone. Our goal was to determine if 
pharmacists in Camden County are aware of the OPA and 
stocking naloxone in their pharmacies for ready availability to 
patients in need, and would specific educational interventions 
improve pharmacists’ knowledge and engagement.
1. Hosted free continuing education (CE) event for Camden County 
retail pharmacists with information regarding opioids, naloxone, 
and the OPA.
2. Anonymously surveyed Camden County pharmacists via in-person 
or phone surveys on their knowledge of the OPA and naloxone 
availability at their pharmacy.
3. Repeated steps 1 and 2 approximately 6 months after initial CE 
event.
Inclusion Criteria: Pharmacy in Camden County
Exclusion Criteria: Pharmacist declined to participate; pharmacy 
unable to be located or contacted
There was an increase in pharmacist knowledge of the 
OPA in the time between July 2017 and February 2018. 
Pharmacists working at chain pharmacies were more likely 
to be aware of the law and carry naloxone than those at 
independent pharmacies. The results may be generalizable 
due to the socioeconomic diversity of Camden County.
We successfully surveyed over 80% of pharmacies in Camden County during both survey periods. 
Of the 97 total included pharmacies in July 2017, 63% reported knowledge of the OPA and 62% 
reported carrying naloxone. In February 2018, after the second education event, 82% reported 
knowledge of the OPA and 80%  reported carrying naloxone.
● Between 2017 and 2018, there were statistically significant increases in the number of 
pharmacists with knowledge of the OPA (p-value < 0.005) and the number of pharmacies 
carrying naloxone in stock (p-value < 0.005) 
● In both 2017 and 2018, a statistically significant greater number of chain pharmacies had 
knowledge of the OPA as compared to independent pharmacies (p-value < 0.005)
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Survey Response 2017 2018
Observed # Chi-Square Statistic Observed # Chi-Square Statistic
Knowledge of OPA 61 1.25 79 1.26
Lack of knowledge 
of OPA
36 3.29 17 3.33
Chi-square 9.1207
P-value 0.002527
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